Cancer

Title Average Ratingsort ascending
Bcl-2 overexpression protects human keratinocyte cells from Ukrain-induced apoptosis but not from G2/M arrest. 60.00%
Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. 60.00%
The influence of the novel drug Ukrain on hemo- and immunopoiesis at the time of its maximum radioprotective effect 60.00%
A case of metronomic chemotherapy as an alternative cancer therapy for palliation 60.00%
Does the Ukrain preparation protect mice against lethal doses of bacteria? 60.00%
The effects of thiophosphoric acid (Ukrain) on cervical cancer, stage IB bulky 60.00%
Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status 60.00%
Low-dose methotrexate and cyclophosphamide in recurrent ovarian cancer. 60.00%
Review. Current role and future perspectives of hyperthermia for prostate cancer treatment. 60.00%
Amino acid conferred protection against melphalan: comparison of amino acids which reduce melphalan toxicity to murine bone marr 60.00%
Vitamin D and prostate cancer risk: a review of the epidemiological literature. 60.00%
New biochemical mechanisms of the anticancer effect of Ukrain in the treatment of cancer of the urinary bladder 60.00%
Anti-angiogenic therapies for metastatic colorectal cancer. 60.00%
Combined therapy with Ukrain and chemotherapy in ovarian cancer (case report) 60.00%
Theoretical grounds and experimental confirmation of the antiviral effect of the 60.00%
The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary stu 60.00%
Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. 60.00%
Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase. 60.00%
Clinical management of adrenocortical carcinoma 60.00%
Antiangiogenic drugs currently used for colorectal cancer: what other pathways can we target to prolong responses? 60.00%
Ukrain treatment in carcinoma of the cervix (case report) 60.00%
Nuts and green tea key to cancer treatment? 60.00%
Clinical studies of Ukrain in healthy volunteers (phase 1). 60.00%
Hypoxia-inducible factor-1alpha modulation in combination with anti-angiogenic therapy. 60.00%
Cancer mortality in six lowest versus six highest elevation jurisdictions in the u.s. 60.00%
Significance of thymidine phosphorylase in metronomic chemotherapy using CPT-11 and doxifluridine for advanced colorectal...... 60.00%
Is there a role for herbal medicine in the treatment of pancreatic cancer?. Highlights from the "44th ASCO Annual Meeting". 60.00%
Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary 60.00%
Ukrain therapy of stage T1N0M0 bladder cancer patients 60.00%
Biophysiological effects of Ukrain therapy in a patient with breast cancer (case report) 60.00%
Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo 60.00%
Enhanced proliferation and potassium conductance of Schwann cells isolated from NF2 schwannomas can be reduced by quinidine. 60.00%
A phase II clinical trial of sorafenib in androgen-independent prostate cancer. 60.00%
Programmed drug delivery: nanosystems for tumor targeting. 60.00%
Multicenter phase II study of temozolomide therapy for brain metastasis in patients with malignant melanoma, breast cancer...... 60.00%
Is there a standard of care for the management of advanced pancreatic cancer?. Highlights from the Gastrointestinal Cancers Symp 60.00%
N-Acetylcysteine: Multiple Clinical Applications 60.00%
Artemisinin induces doxorubicin resistance in human colon cancer cells via calcium-dependent activation of HIF-1alpha and P-glyc 60.00%
Update on pilot study on antitumor efficacy of intravenously applied synergistic combinations of diflunisal, PAS, and aspirin in patients with advanced solid tumors. 60.00%
Review on molecular and therapeutic potential of thymoquinone in cancer. 60.00%
Oncolytic virus therapy for malignant brain tumors 60.00%
Cysteine proteinases and their inhibitors in the development of mouse HA-1 hepatoma and antineoplastic therapy 60.00%
Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. 60.00%
Metronomic administration of ibandronate and its anti-angiogenic effects in vitro. 60.00%
Ukrain both as an anti cancer and immunoregulatory agent 60.00%
Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer with metronomic UFT + CP 60.00%
Radiofrequency ablation 60.00%
The story of the cancer medicine Ukrain and Wassil Nowicky 55.00%
Propolis Extract (Bio 30) Suppresses the Growth of Human Neurofibromatosis (NF) Tumor Xenografts in Mice 55.00%
Lymphocyte subsets in patients with lung cancer treated with thiophosphoric acid 55.00%
Opioid growth factor improves clinical benefit and survival in patients with advanced pancreatic cancer. 55.00%
Removed from Pubmed because of suspicion of scientific fraud: Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF). 55.00%
A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin.... 50.00%
MET in small cell lung carcinoma (SCLC): Effects of a MET inhibitor in SCLC cell lines and prognostic role of MET status in pati 50.00%
Evaluation of recombinant bacillus Calmette-Guerin expressing pertussis toxin in bladder cancer. 50.00%
Post-mortem studies in glioblastoma patients treated with thermotherapy using magnetic nanoparticles. 50.00%
Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. 50.00%
Ukrain (NSC-631570) influences on bone status: a review. 50.00%
Systematic review: Cyclo-oxygenase-2 in human oesophageal adenocarcinogenesis. 50.00%
Ukrain in the treatment of urethral recurrent carcinoma (case report) 50.00%
Ukrain with chemotherapy in malignant melanoma (case report) 50.00%
Modification of antinociceptive action of morphine by Ukrain in rodents 50.00%
Inhibitive effect of artemether on tumor growth and angiogenesis in the rat C6 orthotopic brain gliomas model. 50.00%
Immunologic effector mechanisms of a standardized mistletoe extract on the function of human monocytes and lymphocytes in vitro, 50.00%
A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung 50.00%
Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy 50.00%
Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer. 50.00%
Long-term safety of BLP25 liposome vaccine (L-BLP25) in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC). 50.00%
Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. 50.00%
Comparative evaluation of blood plasma and tumor tissue amino acid pool in radiation or neoadjuvant preoperative therapies.... 50.00%
A study of the influence of a novel drug Ukrain on in vivo effects of low-dose ionizing radiation 50.00%
Morphometric and kinetic analysis of the growth of experimental sarcoma-45 in the presence of Ukrain 50.00%
Randomized and non-randomized prospective controlled cohort studies in matched pair design for the long-term therapy of corpus u 50.00%
Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. 50.00%
Chemoradiotherapy in malignant glioma: standard of care and future directions. 50.00%
Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities 50.00%
Inhibition of angiogenesis by non-toxic doses of temozolomide. 50.00%
Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme. 50.00%
The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary 50.00%
Influence of Ukrain on the nuclear thyroid hormone receptors after short-term gamma-irradiation. 50.00%
Roles of sildenafil in enhancing drug sensitivity in cancer. 50.00%
Comparative in vitro study of the effects of the new antitumor drug Ukrain and several cytostatic agents on the thiol groups in 50.00%
Ukrain treatment in a patient with non-seminomatous germ-cell tumour of testis (case report) 50.00%
Case report of a pituitary macroadenoma treated with artemether. 50.00%
Die Rolle von Boswellia-Säuren in der Therapie maligner Gliome: Methodische Mängel 50.00%
Annonacin, a mono-tetrahydrofuran acetogenin, arrests cancer cells at the G1 phase and causes cytotoxicity in a Bax- and caspase 50.00%
Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. 50.00%
WITHDRAWN: Ovarian ablation for early breast cancer. 50.00%
Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors. 50.00%
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. 50.00%
Five novel mono-tetrahydrofuran ring acetogenins from the seeds of Annona muricata. 50.00%
Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofe 50.00%
A phase II trial of thalidomide plus tegafur/uracil for patients with advanced/metastatic hepatocellular carcinoma (HCC) 50.00%
Resveratrol inhibits mTOR signaling by promoting the interaction between mTOR and DEPTOR. 50.00%
Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and 50.00%
c-myc amplification is associated with HER2 amplification and closely linked with cell proliferation in tissue microarray of non 50.00%
Results of Ukrain monotherapy of prostate cancer 50.00%
Glioblastoma Multiforme 50.00%
Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. 50.00%
Carbon-ion treatment 50.00%

Pages